Tactile Systems Technology (NASDAQ:TCMD) Announces Quarterly Earnings Results

Tactile Systems Technology (NASDAQ:TCMD) announced its earnings results on Monday. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03, FiscalAI reports. Tactile Systems Technology had a return on equity of 11.49% and a net margin of 7.10%. The business had revenue of $91.86 million for the quarter, compared to analysts’ expectations of $91.99 million.

Here are the key takeaways from Tactile Systems Technology’s conference call:

• Positive Sentiment: Lymphedema revenue grew 13% year over year to $81.8 million, with Medicare returning to 11% growth after prior-authorization timing disruptions stabilized. Management cited increased clinic visits, referring clinics, and sales-force productivity as drivers of continued momentum.
• Positive Sentiment: Tactile maintained 2026 revenue guidance of $360 million to $366 million and raised adjusted EBITDA guidance to $50 million-$52 million, supported by gross-margin expansion, strong cash generation, and expected operating leverage.
• Negative Sentiment: Airway-clearance revenue fell 25% to $10 million as several DME customers took longer than expected to work through excess inventory during the AffloVest transition. Management expects sequential improvement in Q4 but now projects full-year airway-clearance revenue to decline by mid- to high-single digits.
• Positive Sentiment: The company advanced its growth pipeline through FDA clearance of an expanded LymphaTech 3D Scanner indication, progress toward a Category III CPT code, the Flexitouch Pro 510(k) filing, and plans for a late-Q4 VA pilot of MyoSleeve.
• Neutral Sentiment: Management expects further long-term growth from improving referral-to-shipment conversion through AI-enabled order operations and the newly created COO role, but emphasized that new products, payer wins, and diagnostic reimbursement are likely to build gradually rather than create an immediate acceleration.

Tactile Systems Technology Stock Down 0.7%

NASDAQ:TCMD opened at $22.87 on Tuesday. Tactile Systems Technology has a 52 week low of $15.32 and a 52 week high of $37.77. The firm has a 50 day moving average of $22.72 and a 200 day moving average of $25.91. The stock has a market capitalization of $518.01 million, a price-to-earnings ratio of 22.14 and a beta of 0.82.

Wall Street Analyst Weigh In

TCMD has been the subject of several recent research reports. Wall Street Zen raised Tactile Systems Technology from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings raised Tactile Systems Technology from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, October 13th. Finally, BTIG Research cut their target price on Tactile Systems Technology from $39.00 to $35.00 and set a “buy” rating on the stock in a research note on Monday, October 12th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $37.60.

Trending Headlines about Tactile Systems Technology

Here are the key news stories impacting Tactile Systems Technology this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.31 per share, exceeding estimates ranging from $0.28 to $0.30. The earnings beat provides support for the stock, although profit declined from $0.36 per share a year earlier. Tactile Systems Technology Q3 earnings report
• Positive Sentiment: Lymphedema product revenue increased 13% year over year to $81.8 million, reinforcing the company’s core growth strategy. Management also highlighted technology improvements that cut medical-record review times by approximately 50%, potentially improving operating efficiency and patient access. Tactile Systems three key takeaways
• Neutral Sentiment: Quarterly revenue of $91.86 million was essentially in line with, but slightly below, the $91.99 million analyst consensus. Wall Street Zen’s rating upgrade may provide some incremental investor support, but it does not change the underlying earnings outlook. Wall Street Zen rating upgrade
• Negative Sentiment: Growth remains concentrated in lymphedema: the smaller airway-clearance business declined, while a deepening AffloVest inventory issue adds execution risk and could weigh on future sales and cash flow. Tactile Medical earnings and AffloVest inventory report
• Negative Sentiment: Higher sales and administrative expenses pushed operating income below the prior-year level, limiting the benefit of revenue growth and raising concerns about margin expansion. Tactile Medical spending and earnings reaction

Insiders Place Their Bets

In other Tactile Systems Technology news, CEO Sheri Dodd sold 10,978 shares of Tactile Systems Technology stock in a transaction on Monday, August 10th. The shares were sold at an average price of $29.44, for a total value of $323,192.32. Following the transaction, the chief executive officer directly owned 232,907 shares of the company’s stock, valued at approximately $6,856,782.08. The trade was a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.10% of the stock is currently owned by company insiders.

Tactile Systems Technology Company Profile

Tactile Systems Technology, doing business as Tactile Medical, develops and provides medical devices and services for people with chronic swelling and related conditions. The company focuses primarily on lymphedema and chronic venous insufficiency, conditions that can cause persistent fluid buildup in the limbs and trunk.

Its principal products include advanced pneumatic compression devices, such as the Flexitouch Plus system for the treatment of lymphedema and the Entre Plus system for home treatment of lymphedema and chronic venous insufficiency.